The arrival of advanced therapies, such as CAR-T cells, immunotherapy or other targeted treatments and their incorporation into the assistance protocols are being able to modify the course of many oncological and hematological pathologies and pose a new challenge for oncological pharmacists, which must be maintained continuously updated.
The Spanish Society of Hospital Pharmacy (SEFH) joins the World Cancer Day promoted by the World Health Organization, the International Cancer Research Center (CIIC) and the International Union Against Cancer (UICC) recalling the importance of promotion of healthy living habits and research.
Dr. José Antonio Marcos, from the Board of the SEFH, wanted to underline that, “on a day like February 4, World Cancer Day, it is necessary to remember that for the prevention of cancer it is essential to lead a lifestyle healthy. Toxic habits such as tobacco or alcohol abuse, together with factors such as obesity, sedentary lifestyle and sun exposure are related to the appearance of different types of cancer, so from our Society we remember that abandoning these risk factors , will mean a reduction in this disease and the reduction of possible relapses in these patients. ”
In addition, the SEFH is committed to work in the Society’s Oncology Pharmacy group (GEDEFO-SEFH) whose mission is to provide quality pharmaceutical care to achieve maximum clinical benefit and contribute to improving the health outcomes of cancer patients and Hematological in an efficient way. One of the key objectives of GEDEFO is to continue strengthening the role of the oncology pharmacist in the comprehensive care of cancer patients as members of the multidisciplinary team. In this sense, Dr. Estela Moreno, coordinator of GEDEFO, emphasizes that, “in recent years we have worked to improve information and education from pharmaceutical care consultations, redirected towards the CMO model (Capacity, Motivation, Opportunity), with the elaboration of information sheets adapted to the needs of the patients and with supporting documents for the pharmaceutical validation, which have a very positive impact on the quality of the care the patient receives ”.
GEDEFO continues to collaborate in the positioning of new drugs and indications, based on scientific evidence and criteria of effectiveness, taking advantage of the specific training of its members on these issues. It has increased its collaboration with other scientific societies and patient associations and has been actively integrated into national and international medical societies such as the SEHOP group or the EBMT.
The arrival of advanced therapies, such as CAR-T cells, immunotherapy or other targeted treatments and their incorporation into the assistance protocols are being able to modify the course of many oncological and hematological pathologies and pose a new challenge for oncological pharmacists, which must be maintained continuously updated. “The training is key and we are committed to high-level activities such as the BPS specialization scholarships or the UIMP Master’s Degree in Immunooncology, in addition to the close collaboration between all members, seeking to learn from each other,” concludes Dr. Estela Moreno .
In Distefar, we believe that the continuous training of all health personnel is essential. Only then can we advance in therapies such as those for diseases such as cancer.